Monday, May 08, 2017 9:01:45 AM
Therapix Biosciences
As previously reported, this investigator initiated study, is projected to be initiated during the third quarter of 2017, subject to receiving necessary regulatory approvals in Germany. The study will be conducted at Hannover Medical School in Germany under the leadership of principal investigator, Professor Kirsten Muller-Vahl. The study will be a randomized, double-blind, placebo controlled cross-over proof-of-concept Phase II clinical study to evaluate the safety, tolerability and efficacy of up to twice daily oral THX-TS01 in treating adults with Tourette Syndrome (the "Hannover Study"). Each subject will be randomized to receive either THX-TS01 or placebo in a 1:1 ratio via oral administration. A total of 20 patients will be evaluated in a cross-over design. In the first stage, the patients will be randomized to either treatment or placebo and will be treated for a duration of 13 weeks. Afterwards, the patients will be crossed-over and will be treated for an additional 13 weeks; patients who initially received placebo will receive treatment and vice versa. The primary endpoint of the Hannover Study is to evaluate the safety, tolerance and efficacy of THX-TS01. The primary efficacy endpoint will be measured according to Yale Global Tic Severity Scale Total Tic Score, a widely-accepted index for assessing symptom severity and frequency. In addition, the effect of THX-TS01 will be evaluated by several secondary endpoints, including additional scales for measuring tics severity as well as other mental disorders that often accompany Tourette Syndrome, including OCD and ADHD.
"The therapeutic effect of THC in several CNS-related indications has long been established and my lab at Hannover Medical Schools feels fortunate to have been centrally involved in that research," stated Professor Kirsten Muller-Vahl, department of Psychiatry, Socialpsychiatry and Psychotherapy and head of the Tourette outpatient clinic at Hannover Medical School. Professor Muller-Vahl continued, "This robust study that we are embarking upon with Therapix Biosciences will assess the potential synergistic effect of THC in combination with PEA, in what my esteemed colleague Professor Raphael Mechoulam coined the 'Entourage Effect' many years ago. We're enthusiastic to be conducting this study, and optimistic about its findings," concluded Professor Muller-Vahl.
Dr. Elran Haber, Therapix's Chief Executive Officer, stated "We're excited to embark upon the Hannover Study. Hannover Medical School is well regarded as a center of excellence in this area of research, and Professor Muller-Vahl is a recognized key opinion leader in both cannabinoid-based therapeutics and Tourette Syndrome." Dr. Haber concluded, "We're optimistic that the Hannover Study, in conjunction with our currently ongoing study at Yale University, will support earlier research done with cannabinoid-based therapies and may suggest that THX-TS01 is a safe and efficacious treatment for this highly debilitating disease with high unmet medical need."
Recent SPRC News
- SciSparc to Acquire AutoMax • GlobeNewswire Inc. • 04/11/2024 12:15:00 PM
- SciSparc: MitoCareX Unveils Groundbreaking Discovery of Small Molecule Structure in Anti-Cancer Research • GlobeNewswire Inc. • 03/21/2024 12:58:00 PM
- SciSparc Granted Another Patent, Strengthening its Core Technology in Canada • GlobeNewswire Inc. • 03/18/2024 11:29:00 AM
- SciSparc Achieves Major Milestone with First Patient Dosed in Autism Spectrum Disorder Clinical Trial • GlobeNewswire Inc. • 03/14/2024 12:49:00 PM
- SciSparc: MitoCareX Reveals Promising Results with Discovery of Novel Anti-Cancer Small Molecule Structure • GlobeNewswire Inc. • 03/12/2024 12:14:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/08/2024 02:00:02 PM
- SciSparc Announces Enrollment of First Patient for its Clinical Trial for Children with Autism Spectrum Disorder • GlobeNewswire Inc. • 03/08/2024 12:11:00 PM
- SciSparc Granted Patent for Core Technology in Multiple Jurisdictions in Europe • GlobeNewswire Inc. • 03/07/2024 12:49:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 03/07/2024 05:15:11 AM
- SciSparc Issued Canadian Patent for Opioids Reduction Use in Pain Management Technology • GlobeNewswire Inc. • 03/06/2024 09:41:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/29/2024 02:07:12 PM
- SciSparc Delivers Treatment for Autism Spectrum Disorder Clinical Trial Enabling Commencement of Dosing • GlobeNewswire Inc. • 02/29/2024 01:35:00 PM
- Form F-1 - Registration statement for certain foreign private issuers • Edgar (US Regulatory) • 02/27/2024 09:15:05 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/27/2024 01:35:07 PM
- SciSparc-Clearmind Partnership Yields Three New International Patent Applications for MDMA, Ibogaine and Ketamine Compounds • GlobeNewswire Inc. • 02/27/2024 12:58:00 PM
- Clearmind Medicine Submits Three Additional International Patent Applications for Innovative MDMA, Ibogaine and Ketamine Compounds • GlobeNewswire Inc. • 02/27/2024 12:58:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/20/2024 09:27:17 PM
- Clearmind Medicine Submits Three International Patent Applications for Next Generation Classic Psychedelic-Based Compounds • GlobeNewswire Inc. • 02/20/2024 12:14:00 PM
- SciSparc and Clearmind Continue to Strengthen International Patent Portfolio with Next Generation Classic Psychedelic-Based Compounds • GlobeNewswire Inc. • 02/20/2024 12:14:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/12/2024 09:27:31 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/29/2024 09:00:11 PM
- SciSparc Announces Initiation of Patient Recruitment for its Clinical Trial with SCI-210 in Children with Autism Spectrum Disorder • GlobeNewswire Inc. • 01/29/2024 12:18:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/25/2024 02:05:42 PM
- SciSparc Ltd. Announces $20 Million Standby Equity Purchase Agreement • GlobeNewswire Inc. • 01/24/2024 12:42:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/22/2024 11:02:08 AM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM